These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 26844247)

  • 21. [Hypercholesterolemia: Monoclonal antibodies safe and effective].
    Windler E
    Dtsch Med Wochenschr; 2015 May; 140(11):785-6. PubMed ID: 26080713
    [No Abstract]   [Full Text] [Related]  

  • 22. PCSK9 antibodies: A new class of lipid-lowering drugs.
    Gouni-Berthold I
    Atheroscler Suppl; 2015 May; 18():21-7. PubMed ID: 25936300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alirocumab (Praluent) to lower LDL-Cholesterol.
    Med Lett Drugs Ther; 2015 Aug; 57(1475):113-5. PubMed ID: 26262881
    [No Abstract]   [Full Text] [Related]  

  • 24. PCSK9: is it fluoride for cardiology?
    King SB
    JACC Cardiovasc Interv; 2014 Nov; 7(11):1331-2. PubMed ID: 25459045
    [No Abstract]   [Full Text] [Related]  

  • 25. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H; Burns TL; Hilleman DE
    Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antihyperlipidemic therapies targeting PCSK9: Novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Liu MH
    Int J Cardiol; 2015 Sep; 195():212-4. PubMed ID: 26048378
    [No Abstract]   [Full Text] [Related]  

  • 27. [Lipid control in high-risk patients: focus on PCSK9 inhibitors].
    Filardi PP; Paolillo S; Trimarco B
    G Ital Cardiol (Rome); 2015 Jan; 16(1):44-51. PubMed ID: 25689751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia.
    Stawowy P; Just IA; Kaschina E
    Coron Artery Dis; 2014 Jun; 25(4):353-9. PubMed ID: 24667128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. JAMA PATIENT PAGE. PCSK9 Inhibitors for Treating High Cholesterol.
    Jin J
    JAMA; 2015 Dec; 314(21):2320. PubMed ID: 26624842
    [No Abstract]   [Full Text] [Related]  

  • 30. PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
    Yang E
    Clin Pharmacol Ther; 2015 Dec; 98(6):590-601. PubMed ID: 26369501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Finding the Right Price for Improving Care.
    Charlton B
    JAMA Intern Med; 2016 Jan; 176(1):109. PubMed ID: 26662340
    [No Abstract]   [Full Text] [Related]  

  • 32. [Risk of cardiovascular complications cut in half?].
    Einecke D
    MMW Fortschr Med; 2015 Apr; 157(6):26. PubMed ID: 26015190
    [No Abstract]   [Full Text] [Related]  

  • 33. PCSK9 inhibitors.
    Farnier M
    Curr Opin Lipidol; 2013 Jun; 24(3):251-8. PubMed ID: 23652470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Into the future: diversifying lipid management.
    Tonkin AM; Watts GF
    Lancet; 2012 Dec; 380(9858):1971-4. PubMed ID: 23141810
    [No Abstract]   [Full Text] [Related]  

  • 35. [PCSK9 inhibitors. A new approach for treatment of hypercholesterolemia].
    Saußele T
    Med Monatsschr Pharm; 2015 Jul; 38(7):250-7. PubMed ID: 26364362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab.
    Lambert G; Chatelais M; Petrides F; Passard M; Thedrez A; Rye KA; Schwahn U; Gusarova V; Blom DJ; Sasiela W; Marais AD
    J Am Coll Cardiol; 2014 Dec; 64(21):2299-300. PubMed ID: 25456764
    [No Abstract]   [Full Text] [Related]  

  • 37. [PCSK9 inhibitors: new treatment to lower cholesterol].
    Gencer B; Rodondi N; Mach F
    Rev Med Suisse; 2016 Mar; 12(508):440-2, 444. PubMed ID: 27089600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PCSK9 and its modulation.
    Cui CJ; Li S; Li JJ
    Clin Chim Acta; 2015 Feb; 440():79-86. PubMed ID: 25444750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.
    Shimada YJ; Cannon CP
    Eur Heart J; 2015 Sep; 36(36):2415-24. PubMed ID: 25971287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperlipidemia and cardiovascular disease: reinforcement for 'lower is better'.
    Burkhardt R
    Curr Opin Lipidol; 2015 Oct; 26(5):468-9. PubMed ID: 26339769
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.